These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

365 related articles for article (PubMed ID: 27127301)

  • 1. Pathogenic role of B-cell receptor signaling and canonical NF-κB activation in mantle cell lymphoma.
    Saba NS; Liu D; Herman SE; Underbayev C; Tian X; Behrend D; Weniger MA; Skarzynski M; Gyamfi J; Fontan L; Melnick A; Grant C; Roschewski M; Navarro A; Beà S; Pittaluga S; Dunleavy K; Wilson WH; Wiestner A
    Blood; 2016 Jul; 128(1):82-92. PubMed ID: 27127301
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibitors of BCR signalling interrupt the survival signal mediated by the micro-environment in mantle cell lymphoma.
    Bernard S; Danglade D; Gardano L; Laguillier C; Lazarian G; Roger C; Thieblemont C; Marzec J; Gribben J; Cymbalista F; Varin-Blank N; Ledoux D; Baran-Marszak F
    Int J Cancer; 2015 Jun; 136(12):2761-74. PubMed ID: 25388373
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cell-cycle reprogramming for PI3K inhibition overrides a relapse-specific C481S BTK mutation revealed by longitudinal functional genomics in mantle cell lymphoma.
    Chiron D; Di Liberto M; Martin P; Huang X; Sharman J; Blecua P; Mathew S; Vijay P; Eng K; Ali S; Johnson A; Chang B; Ely S; Elemento O; Mason CE; Leonard JP; Chen-Kiang S
    Cancer Discov; 2014 Sep; 4(9):1022-35. PubMed ID: 25082755
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synergistic activity of BET protein antagonist-based combinations in mantle cell lymphoma cells sensitive or resistant to ibrutinib.
    Sun B; Shah B; Fiskus W; Qi J; Rajapakshe K; Coarfa C; Li L; Devaraj SG; Sharma S; Zhang L; Wang ML; Saenz DT; Krieger S; Bradner JE; Bhalla KN
    Blood; 2015 Sep; 126(13):1565-74. PubMed ID: 26254443
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HSP90 inhibition overcomes ibrutinib resistance in mantle cell lymphoma.
    Jacobson C; Kopp N; Layer JV; Redd RA; Tschuri S; Haebe S; van Bodegom D; Bird L; Christie AL; Christodoulou A; Saur A; Tivey T; Zapf S; Bararia D; Zimber-Strobl U; Rodig SJ; Weigert O; Weinstock DM
    Blood; 2016 Nov; 128(21):2517-2526. PubMed ID: 27742706
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bruton tyrosine kinase is commonly overexpressed in mantle cell lymphoma and its attenuation by Ibrutinib induces apoptosis.
    Cinar M; Hamedani F; Mo Z; Cinar B; Amin HM; Alkan S
    Leuk Res; 2013 Oct; 37(10):1271-7. PubMed ID: 23962569
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dual BTK/SYK inhibition with CG-806 (luxeptinib) disrupts B-cell receptor and Bcl-2 signaling networks in mantle cell lymphoma.
    Thieme E; Liu T; Bruss N; Roleder C; Lam V; Wang X; Nechiporuk T; Shouse G; Danilova OV; Bottomly D; McWeeney SK; Tyner JW; Kurtz SE; Danilov AV
    Cell Death Dis; 2022 Mar; 13(3):246. PubMed ID: 35296646
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacological and genomic profiling identifies NF-κB-targeted treatment strategies for mantle cell lymphoma.
    Rahal R; Frick M; Romero R; Korn JM; Kridel R; Chan FC; Meissner B; Bhang HE; Ruddy D; Kauffmann A; Farsidjani A; Derti A; Rakiec D; Naylor T; Pfister E; Kovats S; Kim S; Dietze K; Dörken B; Steidl C; Tzankov A; Hummel M; Monahan J; Morrissey MP; Fritsch C; Sellers WR; Cooke VG; Gascoyne RD; Lenz G; Stegmeier F
    Nat Med; 2014 Jan; 20(1):87-92. PubMed ID: 24362935
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cutting Edge: ROR1/CD19 Receptor Complex Promotes Growth of Mantle Cell Lymphoma Cells Independently of the B Cell Receptor-BTK Signaling Pathway.
    Zhang Q; Wang HY; Liu X; Nunez-Cruz S; Jillab M; Melnikov O; Nath K; Glickson J; Wasik MA
    J Immunol; 2019 Oct; 203(8):2043-2048. PubMed ID: 31534006
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stabilization of β-catenin upon B-cell receptor signaling promotes NF-kB target genes transcription in mantle cell lymphoma.
    Lazarian G; Friedrich C; Quinquenel A; Tran J; Ouriemmi S; Dondi E; Martin A; Mihoub I; Chiron D; Bellanger C; Fleury C; Gélébart P; McCormack E; Ledoux D; Thieblemont C; Marzec J; Gribben JG; Cymbalista F; Varin-Blank N; Gardano L; Baran-Marszak F
    Oncogene; 2020 Apr; 39(14):2934-2947. PubMed ID: 32034308
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Distinct patterns of B-cell receptor signaling in non-Hodgkin lymphomas identified by single-cell profiling.
    Myklebust JH; Brody J; Kohrt HE; Kolstad A; Czerwinski DK; Wälchli S; Green MR; Trøen G; Liestøl K; Beiske K; Houot R; Delabie J; Alizadeh AA; Irish JM; Levy R
    Blood; 2017 Feb; 129(6):759-770. PubMed ID: 28011673
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of focal adhesion kinase overcomes resistance of mantle cell lymphoma to ibrutinib in the bone marrow microenvironment.
    Rudelius M; Rosenfeldt MT; Leich E; Rauert-Wunderlich H; Solimando AG; Beilhack A; Ott G; Rosenwald A
    Haematologica; 2018 Jan; 103(1):116-125. PubMed ID: 29079592
    [TBL] [Abstract][Full Text] [Related]  

  • 13. p110α Inhibition Overcomes Stromal Cell-Mediated Ibrutinib Resistance in Mantle Cell Lymphoma.
    Guan J; Huang D; Yakimchuk K; Okret S
    Mol Cancer Ther; 2018 May; 17(5):1090-1100. PubMed ID: 29483220
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Resistance Mutations to BTK Inhibitors Originate From the NF-κB but Not From the PI3K-RAS-MAPK Arm of the B Cell Receptor Signaling Pathway.
    Smith CIE; Burger JA
    Front Immunol; 2021; 12():689472. PubMed ID: 34177947
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ibrutinib inhibits BCR and NF-κB signaling and reduces tumor proliferation in tissue-resident cells of patients with CLL.
    Herman SE; Mustafa RZ; Gyamfi JA; Pittaluga S; Chang S; Chang B; Farooqui M; Wiestner A
    Blood; 2014 May; 123(21):3286-95. PubMed ID: 24659631
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of ibrutinib-sensitive and -resistant mantle lymphoma cells.
    Ma J; Lu P; Guo A; Cheng S; Zong H; Martin P; Coleman M; Wang YL
    Br J Haematol; 2014 Sep; 166(6):849-61. PubMed ID: 24957109
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pleiotropic Action of Novel Bruton's Tyrosine Kinase Inhibitor BGB-3111 in Mantle Cell Lymphoma.
    Li CJ; Jiang C; Liu Y; Bell T; Ma W; Ye Y; Huang S; Guo H; Zhang H; Wang L; Wang J; Nomie K; Zhang L; Wang M
    Mol Cancer Ther; 2019 Feb; 18(2):267-277. PubMed ID: 30413649
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regulation of B cell receptor-dependent NF-κB signaling by the tumor suppressor KLHL14.
    Choi J; Phelan JD; Wright GW; Häupl B; Huang DW; Shaffer AL; Young RM; Wang Z; Zhao H; Yu X; Oellerich T; Staudt LM
    Proc Natl Acad Sci U S A; 2020 Mar; 117(11):6092-6102. PubMed ID: 32127472
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ibrutinib resistance in mantle cell lymphoma: clinical, molecular and treatment aspects.
    Hershkovitz-Rokah O; Pulver D; Lenz G; Shpilberg O
    Br J Haematol; 2018 May; 181(3):306-319. PubMed ID: 29359797
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Concomitant high expression of Toll-like receptor (TLR) and B-cell receptor (BCR) signalling molecules has clinical implications in mantle cell lymphoma.
    Akhter A; Street L; Ghosh S; Burns BF; Elyamany G; Shabani-Rad MT; Stewart DA; Mansoor A
    Hematol Oncol; 2017 Mar; 35(1):79-86. PubMed ID: 26354285
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.